i(3)so3-galactosylceramide and Hypertension

Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended.

Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fenofibrate; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pandemics; Pneumonia, Viral; PPAR alpha; SARS-CoV-2; Sulfoglycosphingolipids; Virus Internalization

Serum sulfatides are critical glycosphingolipids present in lipoproteins that work as modulators of thrombosis and hemostasis. Decreased serum sulfatide levels are suggested by our previous work to be related to cardiovascular disease (CVD). Hypertension, known to be an important risk factor for CVD, may affect serum sulfatide levels. However, how hypertension affects serum sulfatides directly and mechanistically is unknown. To elucidate these possible mechanisms, we investigated changes in serum sulfatide levels and their metabolism using an established experimental model of hypertension that uses continuous infusion of angiotensin II (AngII) into mice. Furthermore, we also examined the effects of four different antihypertensive drugs (losartan, irbesartan, nifedipine, and hydralazine) on serum sulfatide metabolism. Serum levels of sulfatides were found to be decreased in groups in which only hypertension was induced (AngII only), whereas they were increased in groups with reduced blood pressure (antihypertensives only) and ameliorated to increasingly normal levels in groups with induced hypertension that were also treated (AngII+antihypertensives). Changes in serum sulfatides were strongly related to hepatic expression levels of cerebroside sulfotransferase (CST), which is a key enzyme involved in sulfatide synthesis. Furthermore, the current study suggests that the primary factors affecting CST expression are oxidative stress, peroxisome proliferator-activated receptor α activity and blood pressure itself. This study demonstrates that hypertension significantly decreases levels of serum sulfatides by reducing hepatic CST expression via various effects mediated by AngII. Antihypertensive treatments can ameliorate abnormalities in serum sulfatide levels and may partially prevent hypertension related CVD by positively affecting sulfatide metabolism.

Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Hypertension; Liver; Male; Mice, Inbred C57BL; Oxidative Stress; PPAR gamma; Sulfoglycosphingolipids; Sulfotransferases

Hypertension is a major traditional risk factor for atherosclerosis, and carotid artery intima-media thickness (IMT) is considered to be an important marker of atherosclerosis. Sulfatides have been shown to play a role in atherogenesis and vascular inflammation, resulting in atherosclerosis. This study aimed to assess the association between serum sulfatide and carotid artery IMT among hypertensive patients. We chose 60 hypertensive patients and 30 matched healthy controls. All subjects had medical examinations at Hebei General Hospital between March 2011 and March 2012. Measurements and other factors compared included serum sulfatide level, carotid artery IMT, and conventional cardiovascular risk factors. Hypertensive patients had higher BMIs (24.4 ± 7.6 to 23.1 ± 3.1 kg/m(2)), total cholesterol levels (5.5 ± 0.6 to 5.0 ± 1.1 mM), serum sulfatide levels (3.5 ± 3.9 to 8.3 ± 2.7 μM), and carotid artery IMTs (1.06 ± 0.15 to 0.79 ± 0.07 mm) (all P < 0.05) than control patients. Furthermore, the serum sulfatide level positively correlated with carotid IMT in the hypertensive patients (r = 0.39, P = 0.002). Multiple linear regression analysis showed serum sulfatide was an independent risk factor affecting IMT (P = 0.04). These results suggest that serum sulfatide is more strongly associated with carotid artery IMT than other traditional risk factors in hypertensive patients.

Topics: Aged; Atherosclerosis; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Female; Humans; Hypertension; Male; Middle Aged; Risk Factors; Sulfoglycosphingolipids

Sulphatides were assayed in preparations of frontal cortex, neostriatum and hippocampus of 6-month-old male spontaneously hypertensive rats (SHR, systolic pressure 215 +/- 6 mmHg) and age-matched normotensive Wistar-Kyoto (WKY) rats (systolic pressure 143 +/- 6 mmHg) by thin layer chromatography associated with spectrophotometry and histochemistry. The volume of gray and white matter of the above areas was also measured by microanatomical techniques associated with image analysis. Sulphatide levels were unchanged in the frontal cortex and neostriatum and decreased in the hippocampus of SHR in comparison with WKY rats. No changes of metachromatic sulphatide staining were found in the different brain areas investigated of SHR, whereas a decrease of positive metachromatic areas was noticeable in the frontal cortex and neostriatum, but not in the hippocampus of SHR. A reduction of volume of frontal cortex gray and white matter as well as of striosomes and of gray matter of hippocampus was found in SHR. No changes in the total volume of neostriatum and in the volume of white matter of hippocampus were observed between SHR and normotensive WKY rats. These findings, which are consistent with recent evidence of the occurrence of atrophic changes in the brain of SHR, showed that sulphatide levels were decreased in the hippocampus of SHR. In this area no reduction of white matter was observed. Sulphatide concentrations are thought to reflect the status of brain myelinated fibers. The not parallel decrease of sulphatide levels and white matter volume in the majority of brain areas investigated suggests the occurrence in SHR of sulphatide changes not corresponding simply to a reduction of myelinated pathways.

Topics: Animals; Atrophy; Brain; Frontal Lobe; Hippocampus; Hypertension; Male; Neostriatum; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sulfoglycosphingolipids